Sonoma Pharmaceuticals (SNOA) director receives 10,000-share stock option grant

Rhea-AI Filing Summary

Sonoma Pharmaceuticals, Inc. director John McLaughlin received a grant of stock options for 10,000 shares of common stock at an exercise price of $1.26 per share. The options vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control. Following this award, he holds stock options covering 30,001 shares directly.

Insights

Equity compensation analyst

Director received routine stock option grant as board compensation.

Director John McLaughlin was granted stock options for 10,000 shares of Sonoma Pharmaceuticals common stock at an exercise price of $1.26 per share. The award is described as compensation for services on the Board of Directors, indicating a standard equity-based fee structure rather than an open-market transaction.

The options vest one-third on July 9, 2027, one-third on July 9, 2028, and one-third on July 9, 2029, or upon a change of control. This multi-year vesting schedule ties a portion of the director's compensation to longer-term company performance and continued service. After the grant, McLaughlin holds options on 30,001 shares, providing meaningful but not outsized equity exposure.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MCLAUGHLIN JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	10,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 30,001 shares (Direct)

Footnotes (2)

1. F1. The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control.
2. F2. The options were awarded and granted to Mr. McLaughlin for services performed on the Board of Directors.

Key Figures

Options granted: 10,000 shares Exercise price: $1.26 per share Total options after grant: 30,001 shares +2 more

5 metrics

Options granted 10,000 shares Stock options for common stock granted to director John McLaughlin

Exercise price $1.26 per share Conversion or exercise price of newly granted stock options

Total options after grant 30,001 shares Total stock options held by John McLaughlin following the reported grant

Option expiration date July 9, 2036 Expiration date of the granted stock options

Vesting start date July 9, 2027 First one-third tranche of options vests on this date

Key Terms

Stock option, exercise price, change of control, Board of Directors

4 terms

Stock option financial

"Stock option (right to buy)"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "1.2600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change of control financial

"vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

Board of Directors financial

"granted to Mr. McLaughlin for services performed on the Board of Directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

What did Sonoma Pharmaceuticals (SNOA) director John McLaughlin report in this Form 4?

Director John McLaughlin reported a grant of stock options for 10,000 shares of Sonoma Pharmaceuticals common stock, awarded as compensation for his services on the Board of Directors.

What is the exercise price of the stock options granted to John McLaughlin at SNOA?

The stock options granted to John McLaughlin have an exercise price of $1.26 per share, allowing him to buy Sonoma Pharmaceuticals common stock at that price once the options vest.

How do the new Sonoma Pharmaceuticals (SNOA) options granted to John McLaughlin vest?

The options vest in three equal installments: one third on July 9, 2027, one third on July 9, 2028, and one third on July 9, 2029, or upon a change of control.

What is the total stock option position John McLaughlin holds in SNOA after this grant?

Following the grant, John McLaughlin holds stock options covering 30,001 shares of Sonoma Pharmaceuticals common stock, all reported as direct ownership in this Form 4 filing.

When do the newly granted Sonoma Pharmaceuticals (SNOA) options to John McLaughlin expire?

The stock options granted to John McLaughlin expire on July 9, 2036, giving him a long-term window to exercise the right to buy Sonoma Pharmaceuticals common stock.

Why were the Sonoma Pharmaceuticals (SNOA) stock options granted to John McLaughlin?

The filing states the options were awarded and granted to John McLaughlin for services performed on the Board of Directors, indicating they are part of his director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/09/2026 - 08:47 PM Accepted by SEC EDGAR 07/09/2026 - 08:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCLAUGHLIN JOHN

(Last) (First) (Middle)

C/O SONOMA PHARMACEUTICALS, INC.

5445 CONESTOGA COURT, SUITE 150

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sonoma Pharmaceuticals, Inc. [ SNOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$1.26	07/09/2026		A		10,000		(1)	07/09/2036	Common Stock	10,000	(2)	30,001	D

Explanation of Responses:

1. The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control.

2. The options were awarded and granted to Mr. McLaughlin for services performed on the Board of Directors.

	/s/ Amy Trombly as attorney-in-fact	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)